Loading company
Loading
Open Financials ProQR Therapeutics N.V. (PRQR) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | €15.9 million | €18.9 million | -15.9% | 20-F 2026-03-12 · proof |
| Operating income | -€43.4 million | -€30.5 million | 20-F 2026-03-12 · proof | |
| Net income | -€42.2 million | -€27.8 million | 20-F 2026-03-12 · proof | |
| Cash from operating activities | -€52.8 million | -€36.4 million | 20-F 2026-03-12 · proof | |
| Free cash flow | -€53.8 million | -€37.8 million | 20-F 2026-03-12 · proof | |
| Total assets | €112.8 million | €168 million | -32.9% | 20-F 2026-03-12 · proof |
| Total liabilities | €63.4 million | €79.4 million | -20.2% | 20-F 2026-03-12 · proof |
| Cash and cash equivalents | €92.4 million | €149.4 million | -38.1% | 20-F 2026-03-12 · proof |
- What was ProQR Therapeutics N.V. (PRQR)'s revenue in fiscal 2025?
- ProQR Therapeutics N.V. (PRQR) reported revenue of €15.9 million for fiscal 2025 (the year ended Dec 31, 2025), against €18.9 million the year before (-15.9%). Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What was ProQR Therapeutics N.V. (PRQR)'s operating income in fiscal 2025?
- ProQR Therapeutics N.V. (PRQR) reported operating income of -€43.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -€30.5 million the year before. Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What was ProQR Therapeutics N.V. (PRQR)'s net income in fiscal 2025?
- ProQR Therapeutics N.V. (PRQR) reported net income of -€42.2 million for fiscal 2025 (the year ended Dec 31, 2025), against -€27.8 million the year before. Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What was ProQR Therapeutics N.V. (PRQR)'s cash from operating activities in fiscal 2025?
- ProQR Therapeutics N.V. (PRQR) reported cash from operating activities of -€52.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -€36.4 million the year before. Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What was ProQR Therapeutics N.V. (PRQR)'s free cash flow in fiscal 2025?
- ProQR Therapeutics N.V. (PRQR) reported free cash flow of -€53.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -€37.8 million the year before. Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What are ProQR Therapeutics N.V. (PRQR)'s total assets?
- As of Dec 31, 2025, ProQR Therapeutics N.V. (PRQR) reported total assets of €112.8 million, against €168 million a year earlier (-32.9%). Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What are ProQR Therapeutics N.V. (PRQR)'s total liabilities?
- As of Dec 31, 2025, ProQR Therapeutics N.V. (PRQR) reported total liabilities of €63.4 million, against €79.4 million a year earlier (-20.2%). Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
- What are ProQR Therapeutics N.V. (PRQR)'s cash and cash equivalents?
- As of Dec 31, 2025, ProQR Therapeutics N.V. (PRQR) reported cash and cash equivalents of €92.4 million, against €149.4 million a year earlier (-38.1%). Source: the 20-F filed with the SEC on Mar 12, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:PRQR&period_type=annual&limit=5"Information only, not investment advice.